Alterity Therapeutics (ATHE) FCF Margin (2010 - 2019)

Alterity Therapeutics' FCF Margin history runs 6 years deep, the most recent figure standing at 99.71% for Q4 2019.

• In Q4 2019, FCF Margin rose 24.0% year-over-year to 99.71%; the TTM figure through Dec 2021 stood at 48.39% (down 4595.0% YoY), while the FY2024 annual figure was 0.0%, changed 0.0% from the prior year.
• FCF Margin was 99.71% for Q4 2019 at Alterity Therapeutics, roughly flat from 99.95% in the prior quarter.
• In the past five years, FCF Margin ranged from a high of 15.62% in Q4 2016 to a low of 99.95% in Q4 2018.
• Historically, FCF Margin has averaged 78.75% across 4 years, with a median of 99.71% in 2017.
• The sharpest annual moves came in 2017 and 2019: FCF Margin sank 8409 bps in 2017, then gained 24 bps in 2019.
• A 4-year view of FCF Margin shows it stood at 15.62% in 2016, then slumped by 538 bps to 99.72% in 2017, then fell by 0 bps to 99.95% in 2018, then advanced by 0 bps to 99.71% in 2019.
• The last three FCF Margin figures came in at 99.71% (Q4 2019), 99.95% (Q4 2018), and 99.72% (Q4 2017), per Business Quant data.